Source: Annual Congress 2007 - New insights into clinical lung transplantation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Keller, G. Menges, A. Akkar, J. Behr, C. Herpich, K. Sommerer, J. Seitz (Munich, Germany). Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser. Eur Respir J 2007; 30: Suppl. 51, 336

Member's Comments

No comment yet.

Related content which might interest you: A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Preservation of post-transplant lung function with aerosol cyclosporin Source: Eur Respir J 2004; 23: 378-383 Year: 2004 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017 Antimicrobial properties of aerosolized liposomal cyclosporine (L-CsA) in lung transplantation patients – An in vitro study Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010 Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004 In vitro lung deposition evaluation of liposomal Amphotericin B with 6 different nebulizer systems Source: Eur Respir J 2002; 20: Suppl. 38, 16s Year: 2002 Laninamivir’s prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Evaluation of early conversion to prolonged-release tacrolimus in lung transplantation. Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015 Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010